Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001472375-25-000070
Filing Date
2025-06-30
Accepted
2025-06-30 15:51:40
Documents
62
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT FOR THE FISCAL YEAR ENDED MARCH 31, 2025 ixform10k.htm   iXBRL 10-K 606757
2 CERTIFICATION exhibit31-1.htm EX-31 10801
3 CERTIFICATION exhibit31-2.htm EX-31 10836
4 CERTIFICATION exhibit32-1.htm EX-32 4132
5 CERTIFICATION exhibit32-2.htm EX-32 4152
6 regenerexlogo.gif GRAPHIC 5716
  Complete submission text file 0001472375-25-000070.txt   3370998

Data Files

Seq Description Document Type Size
7 SCHEMA DOCUMENT rgpx-20250331.xsd EX-101.SCH 32973
8 CALCULATION LINKBASE DOCUMENT rgpx-20250331_cal.xml EX-101.CAL 42913
9 DEFINITION LINKBASE DOCUMENT rgpx-20250331_def.xml EX-101.DEF 139800
10 LABELS LINKBASE DOCUMENT rgpx-20250331_lab.xml EX-101.LAB 237608
11 PRESENTATION LINKBASE DOCUMENT rgpx-20250331_pre.xml EX-101.PRE 204238
64 EXTRACTED XBRL INSTANCE DOCUMENT ixform10k_htm.xml XML 328960
Mailing Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108
Business Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108 305-927-5191
REGENEREX PHARMA, INC. (Filer) CIK: 0001357878 (see all company filings)

EIN.: 980479983 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-K | Act: 34 | File No.: 000-53230 | Film No.: 251091794
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)